Related Experiment Video
Updated: Jul 20, 2026
07:55
Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
Published on: October 17, 2015
Pin1 in Alzheimer's disease
D Allan Butterfield1, Hafiz Mohmmad Abdul, Wycliffe Opii
1Department of Chemistry, University of Kentucky, Kentucky, USA.
Journal of Neurochemistry
|September 2, 2006
Summary
Pin1, an enzyme involved in protein regulation, may drive Alzheimer's disease (AD) progression. Reduced Pin1 activity and oxidative modification in AD brains suggest its critical role in neurodegeneration and neuronal apoptosis.
Area of Science:
- Neuroscience
- Biochemistry
- Molecular Biology
Background:
- Alzheimer's disease (AD) is characterized by increased amyloid precursor protein (APP) processing and tau hyperphosphorylation.
- These pathological hallmarks lead to beta-amyloid (Abeta) peptide production and neurofibrillary tangles.
- Phosphorylation events are critical in AD pathogenesis and treatment strategies.
Purpose of the Study:
- To review the role of peptidyl-prolyl isomerase Pin1 in Alzheimer's disease.
- To investigate Pin1's potential as a driving force in AD initiation and progression.
- To explore Pin1's involvement in neurodegeneration and neuronal apoptosis in AD.
Main Methods:
- Review of existing literature on Pin1, APP, tau, and AD pathology.
- Analysis of studies showing Pin1 co-localization with phosphorylated tau in AD brains.
- Examination of research on Pin1's interaction with APP and its role in Abeta production.
Main Results:
- Pin1 regulates diverse protein functions, including those implicated in AD.
- Pin1 is co-localized with phosphorylated tau and interacts with APP.
- Pin1 activity is reduced and oxidatively modified in mild cognitive impairment (MCI) and AD brains.
Conclusions:
- Pin1's altered activity and oxidative modification in MCI and AD suggest its involvement in disease pathogenesis.
- Pin1 may be a key factor in the initiation and progression of Alzheimer's disease.
- Understanding Pin1's role is crucial for developing novel therapeutic strategies for AD.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...